Mitigating Risks from Human Xylazine Exposure

The Reagan-Udall Foundation for the FDA, in partnership with the FDA, held a public meeting to explore real-world experiences and scientific evidence on emerging data trends for human xylazine exposure. This report summarizes the meeting that also examined concrete strategies for drug development and clinical research that directly support the mitigation and reduction of risks associated with human exposure to xylazine.